Pancreatic cancer is notoriously challenging to treat, due largely to the fact that the disease is often diagnosed after the cancer has metastasized. As a result, the five-year relative survival rate is just 10 percent....
Every September 24, World Cancer Research Day provides an opportunity to raise awareness about the important role research plays in improving cancer treatments and reducing the global burden of this devastating collection of diseases. ...
The American Association for Cancer Research (AACR) released its annual Cancer Progress Report today. The report serves as an important record of the progress that has been made against cancer in the past year. Now in its 10th...
Supreme Court Justice Ruth Bader Ginsburg is not among us today. Sadly, we lost this iconic, trailblazing leader, who was the second woman to serve on the U.S. Supreme Court, and who was an inspiration and a...
The AACR issues an extensive report on cancer disparities, and more news of the week from Cancer Today.
Racial disparities in incidence and mortality exist for many cancers, prompting researchers to explore social and biological factors that could be responsible. John Carpten, PhD, of the University of Southern California’s Keck School of...
Patients with bladder cancer who are treated with an immunotherapeutic may face worse outcomes if they also take proton pump inhibitors.
The inaugural Cancer Disparities Progress Report, published today by the American Association for Cancer Research (AACR), highlights the urgent need to reduce cancer health disparities and achieve health equity for all people, regardless of race,...
Doctors and researchers point out that instructions on scalp cooling were not formulated with Black patients in mind, and cancer news of the week from the staff of Cancer Today magazine.
A trial of the targeted therapy osimertinib for early-stage lung cancer finds that patients who take it go longer without having a cancer recurrence. Whether that should change clinical practice is under discussion.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More